skip to search skip to navigation skip to main content

Archive: Mergers & Acquisitions

Astellas to Acquire Ogeda SA

05th April 2017 in Mergers & Acquisitions

Acquisition expands Astellas’ late stage clinical pipeline with Fezolinetant Tokyo, Japan and Gosselies, Belgium, April 3, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ogeda SA (CEO:Jean Combalbert, ”Ogeda”) announced today that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire…

Read Full Post

Astellas Announces Transfer of Qutenza™ to Grünenthal

13th December 2016 in Mergers & Acquisitions

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma Europe”) has entered into a definitive agreement with Grünenthal under which Astellas Pharma Europe will transfer the exclusive rights for Qutenza™ (capsaicin 8% patch) in Europe, Middle East and Africa…

Read Full Post

Astellas to Acquire Ganymed Pharmaceuticals

28th October 2016 in Mergers & Acquisitions

Tokyo and Mainz, October 28, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2019 Astellas Pharma